United States Patent 5,453,446: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 5,453,446, titled "Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease," is a significant patent in the pharmaceutical sector. This patent, granted to address the treatment of Parkinson's disease, involves specific chemical compounds and their applications. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Background of the Patent
The patent, filed in 1994 and granted in 1995, aims to overcome the drawbacks of traditional L-Dopa treatment for Parkinson's disease by using R-enantiomers of N-propargyl 1-aminoindan compounds. These compounds are designed to be more effective and have fewer side effects compared to existing treatments[2].
Scope of the Patent
The scope of this patent is narrowly focused on the therapeutic use of specific chemical compounds for treating Parkinson's disease. Here are the key aspects:
Chemical Compounds
The patent revolves around the R-enantiomers of N-propargyl 1-aminoindan compounds. These compounds are synthesized to act as MAO inhibitors, which are crucial in the treatment of Parkinson's disease by preventing the breakdown of dopamine in the brain[2].
Therapeutic Use
The primary use of these compounds is in the treatment of Parkinson's disease. The patent describes how these compounds can be combined with L-Dopa to enhance its efficacy and reduce side effects associated with traditional L-Dopa therapy.
Claims of the Patent
The claims section of the patent is critical as it defines the legal boundaries of the invention. Here are some key points:
Independent Claims
The patent includes several independent claims that describe the specific compounds, their synthesis, and their therapeutic use. For example, Claim 1 might describe the R-enantiomer of N-propargyl 1-aminoindan, while subsequent claims detail its use in combination with L-Dopa and other therapeutic agents[2].
Dependent Claims
Dependent claims further specify the scope of the invention by detailing particular aspects of the compounds, such as their pharmaceutical formulations, dosages, and methods of administration.
Patent Landscape
To understand the significance of this patent, it is essential to look at the broader patent landscape in the pharmaceutical and neurological treatment sectors.
Patent Trends in Pharmaceutical Sector
The pharmaceutical sector is highly competitive and innovation-driven. Patents like US 5,453,446 are crucial for companies to protect their intellectual property and maintain a competitive edge. According to the USPTO, the number of patents granted in the pharmaceutical sector has been steadily increasing, reflecting the ongoing research and development in this field[1].
Technological Fields
The patent falls under the broader category of chemical and pharmaceutical patents. The USPTO classifies such patents under specific technological fields, such as chemistry and instruments, which are part of the 35 technical fields described by the World Intellectual Property Organization (WIPO)[1].
Industry Impact
Patents like US 5,453,446 have a significant impact on the industry by driving innovation and ensuring that new treatments are developed and brought to market. For instance, the development of new MAO inhibitors has led to better treatment options for Parkinson's disease patients, improving their quality of life.
Expiration and Generic Entry
The patent US 5,453,446 has expired, which means that the exclusive rights to the invention are no longer in effect. This expiration allows other companies to develop and market generic versions of the drug, increasing accessibility and reducing costs for patients[5].
Real-World Applications
The practical application of this patent is evident in the treatment of Parkinson's disease. The use of R-enantiomers of N-propargyl 1-aminoindan compounds has provided a more effective and safer alternative to traditional treatments. This aligns with the broader trend of using specific applications of chemical compounds to solve real-world medical problems.
Conclusion and Key Takeaways
- Specific Chemical Compounds: The patent focuses on the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
- Therapeutic Use: The primary use is in combination with L-Dopa to enhance efficacy and reduce side effects.
- Claims: Independent and dependent claims define the scope of the invention, including synthesis, formulation, and administration.
- Patent Landscape: The patent is part of a larger trend in pharmaceutical innovation, classified under chemistry and instruments.
- Industry Impact: The patent has driven innovation in Parkinson's disease treatment and is now open for generic entry.
FAQs
What is the main purpose of United States Patent 5,453,446?
The main purpose of this patent is to describe the use of R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
What are the key compounds described in the patent?
The patent describes the R-enantiomers of N-propargyl 1-aminoindan compounds, which are used as MAO inhibitors in combination with L-Dopa.
How does this patent fit into the broader patent landscape?
This patent is part of the pharmaceutical sector, classified under chemistry and instruments, and contributes to the ongoing innovation in neurological treatments.
Is the patent still in effect?
No, the patent has expired, allowing for generic versions of the drug to be developed and marketed.
What is the impact of this patent on Parkinson's disease treatment?
The patent has led to the development of more effective and safer treatments for Parkinson's disease by introducing new MAO inhibitors.
Sources
- Invention: U.S. and Comparative Global Trends - NCSES, January 2020.
- Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease - Google Patents.
- Patent Claims Research Dataset - USPTO, August 2017.
- Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz, July 2024.
- Pharmaceutical drugs covered by patent 5,453,446 - DrugPatentWatch.
